Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer;Etude comparative du granisetron per os et de l'ondansetron IV chez des patientes recevant une chimiotherapie pour un cancer du sein

Bulletin du Cancer

Volumn 86, Issue 3, 1999, Pages 295-301

  Mabro, May ^a   Kerbrat, Pierre ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b CENTRE EUGÈNE MARQUIS   (France)

Author keywords

5 HT3 antagonist; Antiemetic; Breast cancer; Chemotherapy; Granisetron

Indexed keywords

ANTIINFECTIVE AGENT; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; SEROTONIN 3 ANTAGONIST; ANTIEMETIC AGENT;

ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; MALE; MIDDLE AGED;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIEMETICS; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METOCLOPRAMIDE; MIDDLE AGED; NAUSEA; ONDANSETRON; VOMITING;

EID: 0032968035     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 1989; 8: 1142-9.
2. Laszlo J. Emesis as limiting toxicity in cancer chemotherapy. In: Antiemetics and cancer chemotherapy. Lazlo J, ed. Willimans & Wilkins, Baltimore 1983, 1-5.
3. th ed., 2705-14.
4. Aapro MS. Review of experience with ondansetron and granisetron. Ann Oncol 1993; 4 (suppl. 3): S9-S14.
5. Bonneterre J, Hecquet B, Fenaux I, Delzenne A, Carlier D, Darloy F, et al., pour le Groupe de recherche en cancérologie du Nord. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. A cross-over study. Bull Cancer 1995; 82: 1038-43.
6. Bleiberg HH, Spielmann M, Falkson G, Romain D. Antiemetic treatment with oral granisetron in patients receving moderately emetogenic chemotherapy. A dose-ranging study. Clin Ther 1995; 17: 38-51.
7. Bonneterre J, Chevallier B, Metz R, Fargeot P, Pujade-Lauraine E, Spielmann M, et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide; fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990; 8: 1063-9.
8. Park JO, Rha SY, Yoo NC, Kim JH, Roh JK, Min JS, et al. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Am J Clin Oncol 1997; 20: 569-72.
9. Perez P, Hesketh J, Sandbach J, Reeves J, Chawla S, Markman M, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998; 16: 754-8.
10. Huc Ph, Block S, Carlier D, Darloy F, Bonneterre ME, Bleuse JP, et al., pour le Grecno (Groupe de recherche en cancérologie du Nord). Granisétron (per os) comparé à ondansétron (per os) dans la prévention des nausées et vomissements induits par des chimiothérapies moyennement émétisantes. Bull Cancer 1998; 85: 562-8.
11. Kirchner V, Aapro M, Terrey JP, Alberto P. A double-blind cross-over study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy. Eur J Cancer 1997; 33: 1605-10.
12. Martoni A, Angelelli B, Guaraldi M, Strocchi E, Pannuti F. An open randomized cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing chemotherapy. Eur J Cancer 1996; 32A: 82-5.
13. Massida B, Ionta MT. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor antagonist in moderatly emetogenic chemotherapy. J Chemotherapy 1996; 8: 237-42.
14. Marty M. On behalf of the granisetron study group. A comparison of granisetron as a single agent with conventional combinaison antiemetic therapies in the treatment of cytostatic-induced emesis. Eur J Cancer 1992; 28A (suppl. 1): S12-6.
15. Gralla JG, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998; 16: 68-73.
16. The Italian Group for Antiemetic Research. Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? Ann Oncol 1997; 8: 561-7.
17. Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13: 2408-16.
18. Stewart A, McQuade B, Cronje JDE, Goedhals L, Gudgeon A, Corette L, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double dummy, randomized, parallel-group study. Emesis Study group for Ondansetron Granisetron in Breast Cancer Patients. Oncology 1995; 52: 202-10.
19. Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol 1998; 9: 661-6.
20. Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthaven J, et al., for the National Cancer Institute of Canada Clinical Trials Group. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 1998; 16: 1174-8.